Galena Biopharma, Inc. was a big mover last session, as its shares rose over 19% on the day. The stock rallied after the FDA granted a Fast Track designation to the company’s breast cancer drug, NeuVax. This also led to far more shares changing hands than in a normal session. Yesterday’s rally continues the uptrend for the company, as the stock is now up 60% in the past one-month time frame.

Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.

Galena Biopharma currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

A better-ranked biomedical stock is HESKA CORP , sporting a Zacks Rank #1 (Strong Buy).

Is GALE going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>